The following guideline can be ordered through the address listed in the "Source/Publisher"-category. In cases in which you can order through the Internet we have established a hyperlink.

FDA Guidance for Industry: Bridging for Drug-Device and Biologic-Device Combination Products



This guidance provides recommendations to industry and FDA staff on how to approach 19 bridging in new drug applications (NDAs) or biologics license applications (BLAs) for drug-20 device and biologic-device single entity or copackaged combination products including the 21 following

Go back

GMP Conferences by Topics

Cookies help us in providing our services. By using our services, you agree that we use cookies. Further information